Paper Details
- Home
- Paper Details
Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway.
Author: Anliker-OrtMarion, DingemanseJasper, KaufmannPriska, van den AnkerJohn
Original Abstract of the Article :
The complement system comprises the frontline of the innate immune system. Triggered by pathogenic surface patterns in different pathways, the cascade concludes with the formation of a membrane attack complex (MAC; complement components C5b to C9) and C5a, a potent anaphylatoxin that elicits various...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758461/
データ提供：米国国立医学図書館（NLM）
Targeting the Terminal Complement Pathway: A Novel Approach for Rare Inflammatory Kidney Diseases
The field of [inflammatory kidney diseases] is constantly seeking new therapeutic strategies. This review explores the potential of [complement pathway inhibitors] as treatments for a variety of [rare kidney diseases]. The complement system is a critical component of the [innate immune system] and plays a vital role in [defending the body against pathogens]. However, dysregulation of the complement system can lead to [autoinflammatory diseases] and contribute to [kidney damage]. This review focuses on the [terminal complement pathway] and its role in various kidney diseases, including [lupus nephritis, IgA nephropathy, atypical hemolytic uremic syndrome, C3 glomerulopathy, and antineutrophil cytoplasmic antibody-associated vasculitis].
The Promise of Complement Pathway Inhibitors
The review highlights the potential of [complement pathway inhibitors] as [targeted therapies] for these rare inflammatory kidney diseases. The authors discuss the [mechanisms of action] of various inhibitors targeting the terminal complement pathway, including [eculizumab, C5, C5a, C5aR1, and MAC]. The approval of eculizumab for [paroxysmal nocturnal hematuria] demonstrates the [efficacy and safety] of this approach. It's like finding a new oasis in the desert, a source of hope for patients with these challenging conditions.
The Future of Complement Pathway Inhibition
The review also explores the potential role of [complement inhibitors] in [severe COVID-19] and the link between [increased complement activity and lung damage]. This research is paving the way for new and innovative treatments for [inflammatory kidney diseases] and other conditions that involve the complement system.
Dr.Camel's Conclusion
This review provides a comprehensive overview of the [complement pathway] and its role in [inflammatory kidney diseases]. It presents a compelling case for the development of [complement inhibitors] as targeted therapies, offering new hope for patients with these rare and challenging conditions.
Date :
- Date Completed 2021-01-15
- Date Revised 2022-11-16
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.